The Impact of the COVID-19 Pandemic on Testicular Cancer

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Testicular Cancer COVID-19 Coronaviridae Infections Coronavirus Infections Endocrine Gland Neoplasms Endocrine System Diseases Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Gonadal Disorders Infections Lung Diseases Male Urogenital Diseases Neoplasms Neoplasms by Site Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Testicular Diseases Testicular Neoplasms Urogenital Diseases Urogenital Neoplasms Virus Diseases

Age range

18 year–65 year

Sex eligibility

Male

Study type

Observational

Primary location

Ankara Training and Research Hospital

Ankara, Altindag, 06230, Turkey (Türkiye)

About this study

The rapid spread of the 2019 coronavirus disease (COVID-19) caused by a novel betacoronavirus known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had dramatic effects on individuals and health systems around the world. Beyond those infected with SARS-CoV-2,the intense demand for limited health system resources has led to reduced capacity, rapid depletion of healthcare systems and hospitals becoming a source of virus transmission.

Urology associations and reference centers have issued recommendations to inform urology care during the COVID-19 outbreak. It is essential that urologists give priority to patient safety. Potential delays in the diagnosis and treatment of urological conditions and the additional burden on healthcare resources must be balanced against the risks of exposure to COVID-19. While this situation aims to conserve healthcare resources, it has created the risk of delaying cancer treatment. As a result, the transformation of health services and the increasing interest of the public in avoiding exposure to the disease has led to a decrease in the number of hospital admissions.

The effects of the pandemic on patients with testicular cancer due to a decrease in emergency room and urology clinic admissions are not clear. During theCOVID-19 outbreak, the EAU (European Association of Urology) panel of testicular cancer published an evidence-based guideline. According to this guideline, four priority groups were formed and a certain period of delaying treatment was defined for patients in each group according to their priorities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with testicular cancer in the urology clinic.

Exclusion criteria

Previous history of genitourinary system tumor
Previous history of radiotherapy or chemotherapy

Treatment and study plan

COVID-19 pandemic

Behavioral

Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

Primary outcomes

Rate of tumor stages

Time frame: 2 month

Rate of tumor stages in patients who diagnosed with testicular cancer

Sponsors and collaborators

Lead sponsor

Ankara Training and Research Hospital

Other

Registry information

Official study title

The Impact of the COVID-19 Pandemic on Oncologic Outcomes of Testicular Cancer

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Oct 19, 2021
Registry last updated: Apr 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed